TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of Telemonitoring to Improve Heart Failure Outcomes
Brief Summary: The primary purpose of this study is to determine the effectiveness of telemonitoring compared with usual guideline-based care in preventing hospitalization for heart failure patients.


Options:
A: Arm Label: Standard care; Type: OTHER; Interventions: Behavioral: Standard Care | Arm Label: Sustained Care; Type: EXPERIMENTAL; Interventions: Behavioral: Sustained Care | Intervention Type: BEHAVIORAL; Name: Sustained Care; Assigned to Arm(s): Sustained Care | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard care
B: Intervention Type: BEHAVIORAL; Name: Exercise Counseling; Assigned to Arm(s): N/A
C: Arm Label: UC; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: TM; Type: EXPERIMENTAL; Interventions: Other: Telemonitoring | Intervention Type: OTHER; Name: Telemonitoring; Assigned to Arm(s): TM
D: Arm Label: ATSM Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ATSM Intervention | Arm Label: WAIT LIST Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ATSM Intervention; Assigned to Arm(s): ATSM Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study
Brief Summary: COMPASS-2 is a Phase 4, prospective, randomized, double-blind, placebo-controlled, event-driven study evaluating the effect of bosentan on the time to first confirmed morbidity/mortality event in patients with symptomatic PAH already receiving sildenafil therapy. Patients must have been receiving doses of sildenafil equal to or greater than 20 mg t.i.d. for at least 12 weeks prior to being randomized.

The study continued until the predefined target number of morbidity/mortality events was reached.


Options:
A: Arm Label: Sildenafil High dose; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: Sildenafil Low dose; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: Sildenafil medium dose; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: Sildenafil - Open label Phase; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): Sildenafil High dose | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): Sildenafil Low dose | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): Sildenafil medium dose | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): Sildenafil - Open label Phase
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
C: Arm Label: 20 mg tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 40 mg tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 20 mg tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 40 mg tadalafil
D: Intervention Type: DRUG; Name: Bosentan and Sildenafil; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study
Brief Summary: COMPASS-2 is a Phase 4, prospective, randomized, double-blind, placebo-controlled, event-driven study evaluating the effect of bosentan on the time to first confirmed morbidity/mortality event in patients with symptomatic PAH already receiving sildenafil therapy. Patients must have been receiving doses of sildenafil equal to or greater than 20 mg t.i.d. for at least 12 weeks prior to being randomized.

The study continued until the predefined target number of morbidity/mortality events was reached.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
B: Arm Label: Part 1; Type: EXPERIMENTAL; Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose, Drug: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently) | Arm Label: Part 2; Type: EXPERIMENTAL; Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose, Drug: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently) | Arm Label: Part 3; Type: EXPERIMENTAL; Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose | Intervention Type: DRUG; Name: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose; Assigned to Arm(s): Part 1, Part 2, Part 3 | Intervention Type: DRUG; Name: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently); Assigned to Arm(s): Part 1, Part 2
C: Arm Label: Combination therapy; Type: EXPERIMENTAL; Interventions: Drug: Iloprost, Drug: Bosentan | Arm Label: monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Iloprost; Assigned to Arm(s): Combination therapy | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Combination therapy, monotherapy
D: Arm Label: Combination ambrisentan + tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: ambrisentan, Drug: tadalafil | Arm Label: Monotherapy ambrisentan; Type: ACTIVE_COMPARATOR; Interventions: Drug: ambrisentan | Arm Label: Monotherapy tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: ambrisentan; Assigned to Arm(s): Combination ambrisentan + tadalafil, Monotherapy ambrisentan | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): Combination ambrisentan + tadalafil, Monotherapy tadalafil

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of romiplostim in thrombocytopenic patients with low or Intermediate-1 risk MDS. In addition, the study will evaluate the platelet response to romiplostim.


Options:
A: Arm Label: Eltrombopag; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eltrombopag olamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Eltrombopag olamine; Assigned to Arm(s): Eltrombopag | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Part A: 300 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 700 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1000 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1500 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC QW; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim IV Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Intervention Type: DRUG; Name: Romiplostim; Assigned to Arm(s): Part A: 1000 µg romiplostim, Part A: 1500 µg romiplostim, Part A: 300 µg romiplostim, Part A: 700 µg romiplostim, Part B: 750 µg romiplostim IV Q2W, Part B: 750 µg romiplostim SC Q2W, Part B: 750 µg romiplostim SC QW
C: Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: eltrombopag | Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: eltrombopag | Intervention Type: DRUG; Name: eltrombopag; Assigned to Arm(s): Group A, Group B
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: SB497115; Assigned to Arm(s): Arm 1, Arm 2, Arm 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of romiplostim in thrombocytopenic patients with low or Intermediate-1 risk MDS. In addition, the study will evaluate the platelet response to romiplostim.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Therapeutic platelet transfusion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Prophylactic platelet transfusion | Intervention Type: BIOLOGICAL; Name: Prophylactic platelet transfusion; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Therapeutic platelet transfusion; Assigned to Arm(s): 1
B: Intervention Type: PROCEDURE; Name: low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9); Assigned to Arm(s): N/A
C: Arm Label: Eltrombopag; Type: EXPERIMENTAL; Interventions: Drug: Eltrombopag | Intervention Type: DRUG; Name: Eltrombopag; Assigned to Arm(s): Eltrombopag
D: Arm Label: Part A: 300 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 700 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1000 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1500 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC QW; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim IV Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Intervention Type: DRUG; Name: Romiplostim; Assigned to Arm(s): Part A: 1000 µg romiplostim, Part A: 1500 µg romiplostim, Part A: 300 µg romiplostim, Part A: 700 µg romiplostim, Part B: 750 µg romiplostim IV Q2W, Part B: 750 µg romiplostim SC Q2W, Part B: 750 µg romiplostim SC QW

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of romiplostim in thrombocytopenic patients with low or Intermediate-1 risk MDS. In addition, the study will evaluate the platelet response to romiplostim.


Options:
A: Arm Label: Azacitidine; Type: EXPERIMENTAL; Interventions: Drug: Azacitidine | Arm Label: Conventional Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Physician Choice | Intervention Type: DRUG; Name: Azacitidine; Assigned to Arm(s): Azacitidine | Intervention Type: OTHER; Name: Physician Choice; Assigned to Arm(s): Conventional Care
B: Arm Label: Part A: 300 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 700 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1000 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1500 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC QW; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim IV Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Intervention Type: DRUG; Name: Romiplostim; Assigned to Arm(s): Part A: 1000 µg romiplostim, Part A: 1500 µg romiplostim, Part A: 300 µg romiplostim, Part A: 700 µg romiplostim, Part B: 750 µg romiplostim IV Q2W, Part B: 750 µg romiplostim SC Q2W, Part B: 750 µg romiplostim SC QW
C: Arm Label: Eltrombopag; Type: ACTIVE_COMPARATOR; Interventions: Drug: eltrombopag olamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: eltrombopag olamine; Assigned to Arm(s): Eltrombopag | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: lenalidomide | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): Lenalidomide

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double Blind, Randomized, Placebo Controlled Trial With Metformin in Non-Alcoholic Fatty Liver Disease (NAFLD)
Brief Summary: The study evaluates the use of the antidiabetic medicine metformin in nonalcoholic fatty liver disease.


Options:
A: Arm Label: GFT505 80mg; Type: EXPERIMENTAL; Interventions: Drug: GFT505 80mg | Arm Label: GFT505 120mg; Type: EXPERIMENTAL; Interventions: Drug: GFT505 120mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GFT505 80mg; Assigned to Arm(s): GFT505 80mg | Intervention Type: DRUG; Name: GFT505 120mg; Assigned to Arm(s): GFT505 120mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 25 mg INT-747; Type: ACTIVE_COMPARATOR; Interventions: Drug: INT-747 | Arm Label: 50 mg INT-747; Type: ACTIVE_COMPARATOR; Interventions: Drug: INT-747 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: INT-747; Assigned to Arm(s): 25 mg INT-747, 50 mg INT-747 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone/Vitamin E | Intervention Type: DRUG; Name: Spironolactone/Vitamin E; Assigned to Arm(s): Vitamin E
D: Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Trial of Polyphenon E for Cervical Cancer Prevention
Brief Summary: This randomized phase II trial is studying green tea extract to see how well it works compared to a placebo in preventing cervical cancer in patients with human papillomavirus and low-grade cervical intraepithelial neoplasia. Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. The use of green tea extract may stop cervical cancer from forming in patients with human papillomavirus and low-grade cervical intraepithelial neoplasia. It is not yet known whether green tea extract is more effective than a placebo in preventing cervical cancer in patients with human papillomavirus and low-grade cervical intraepithelial neoplasia.


Options:
A: Arm Label: Arm I (FO, GT catechin extract); Type: EXPERIMENTAL; Interventions: Dietary Supplement: green tea catechin extract, Dietary Supplement: fish oil | Arm Label: ArmII (FO placebo, GT catechin extract); Type: EXPERIMENTAL; Interventions: Dietary Supplement: green tea catechin extract, Other: placebo | Arm Label: Arm III (FO, GT placebo); Type: EXPERIMENTAL; Interventions: Dietary Supplement: fish oil, Other: placebo | Arm Label: Arm IV (FO placebo, GT placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: green tea catechin extract; Assigned to Arm(s): Arm I (FO, GT catechin extract), ArmII (FO placebo, GT catechin extract) | Intervention Type: DIETARY_SUPPLEMENT; Name: fish oil; Assigned to Arm(s): Arm I (FO, GT catechin extract), Arm III (FO, GT placebo) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm III (FO, GT placebo), Arm IV (FO placebo, GT placebo) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm IV (FO placebo, GT placebo), ArmII (FO placebo, GT catechin extract)
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: GTE group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: GTE (green tea extract) | Intervention Type: DIETARY_SUPPLEMENT; Name: GTE (green tea extract); Assigned to Arm(s): GTE group
C: Arm Label: Polyphenon E Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyphenon E | Arm Label: Placebo Administration; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Polyphenon E; Assigned to Arm(s): Polyphenon E Treatment | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Administration
D: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Dietary Supplement: defined green tea catechin extract, Other: laboratory biomarker analysis | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm II | Intervention Type: DIETARY_SUPPLEMENT; Name: defined green tea catechin extract; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm I, Arm II

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RENEW: Reach Out to Enhance Wellness in Older Survivors
Brief Summary: RATIONALE: Exercise and dietary counseling may improve physical activity, nutrition, and quality of life in older long-term cancer survivors who are overweight.

PURPOSE: This randomized clinical trial is studying two different schedules of exercise and dietary counseling to compare how well they work in improving physical activity, nutrition, and quality of life in older long-term cancer survivors who are overweight.


Options:
A: Arm Label: Shape-Up following cancer treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Shape-Up following cancer treatment | Arm Label: Control intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shape-Up following cancer treatment; Assigned to Arm(s): Shape-Up following cancer treatment
B: Arm Label: Wait-list control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: behavioral dietary and exercise intervention | Intervention Type: BEHAVIORAL; Name: behavioral dietary and exercise intervention; Assigned to Arm(s): Lifestyle counseling
C: Arm Label: Less Intensive Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Less Intensive | Arm Label: Intensive Group; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Group | Intervention Type: BEHAVIORAL; Name: Less Intensive; Assigned to Arm(s): Less Intensive Group | Intervention Type: BEHAVIORAL; Name: Intensive Group; Assigned to Arm(s): Intensive Group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy CBT) for weight loss | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy CBT) for weight loss; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RENEW: Reach Out to Enhance Wellness in Older Survivors
Brief Summary: RATIONALE: Exercise and dietary counseling may improve physical activity, nutrition, and quality of life in older long-term cancer survivors who are overweight.

PURPOSE: This randomized clinical trial is studying two different schedules of exercise and dietary counseling to compare how well they work in improving physical activity, nutrition, and quality of life in older long-term cancer survivors who are overweight.


Options:
A: Arm Label: Survivorship Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Survivorship Intervention | Arm Label: Facing Forward; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Facing Forward | Intervention Type: BEHAVIORAL; Name: Survivorship Intervention; Assigned to Arm(s): Survivorship Intervention | Intervention Type: BEHAVIORAL; Name: Facing Forward; Assigned to Arm(s): Facing Forward
B: Intervention Type: DEVICE; Name: Pedometer; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Exercise guidebook; Assigned to Arm(s): N/A
C: Arm Label: Wait-list control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: behavioral dietary and exercise intervention | Intervention Type: BEHAVIORAL; Name: behavioral dietary and exercise intervention; Assigned to Arm(s): Lifestyle counseling
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga | Arm Label: 2; Type: OTHER; Interventions: Other: Delayed yoga classes | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Delayed yoga classes; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RENEW: Reach Out to Enhance Wellness in Older Survivors
Brief Summary: RATIONALE: Exercise and dietary counseling may improve physical activity, nutrition, and quality of life in older long-term cancer survivors who are overweight.

PURPOSE: This randomized clinical trial is studying two different schedules of exercise and dietary counseling to compare how well they work in improving physical activity, nutrition, and quality of life in older long-term cancer survivors who are overweight.


Options:
A: Arm Label: Yoga Group A: Minimum Exposure; Type: EXPERIMENTAL; Interventions: Other: Yoga | Arm Label: Yoga Group B: Medium Exposure; Type: EXPERIMENTAL; Interventions: Other: Yoga | Arm Label: Yoga Group C: Maximum Exposure; Type: EXPERIMENTAL; Interventions: Other: Yoga | Intervention Type: OTHER; Name: Yoga; Assigned to Arm(s): Yoga Group A: Minimum Exposure, Yoga Group B: Medium Exposure, Yoga Group C: Maximum Exposure
B: Arm Label: Rectal Cancer; Type: N/A; Interventions: N/A
C: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: Wait-list control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: behavioral dietary and exercise intervention | Intervention Type: BEHAVIORAL; Name: behavioral dietary and exercise intervention; Assigned to Arm(s): Lifestyle counseling

Answer: D